GT BIOPHARMA, INC. Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price
GT BIOPHARMA, INC. (GTBP) had Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price of $2.11 per share as of 2024-10-17, per its 10-K filed 2025-02-21.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 · last filed 2025-02-21
- 2024-10-17: Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price $2.11.
- 2023-05-31: Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price $25.50.
- 2023-05-15: Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price $10.50; Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price as first filed $0.35.
- 2023-01-27: Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price $25.50; Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price as first filed $0.85.
| Period end | Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price | Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price as first filed |
|---|---|---|
| 2024-10-17 | $2.11 10-K · filed 2025-02-21 | |
| 2023-05-31 | $25.50 10-K · filed 2025-02-21 | |
| 2023-05-15 | $10.50 10-Q · filed 2024-11-14 | $0.35 10-Q · filed 2023-08-07 |
| 2023-01-27 | $25.50 10-Q · filed 2024-11-14 | $0.85 10-Q · filed 2023-05-15 |
| 2023-01-01 | $10.50 10-K · filed 2025-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |